Oh, joy! The medical world has been blessed with yet another wonder of modern science: bispecific antibodies (BsAbs) that cozy up to both CD3 and CD20, promising to be the next big thing for B-cell non-Hodgkin lymphoma patients. These multitasking marvels have been wowing the crowds, especially those who’ve already been through the healthcare wringer, and have even managed to snag a few regulatory thumbs-ups around the globe. But wait—there’s a catch! (Isn’t there always?)

These off-the-shelf miracles come with a side of spicy T-cell activation that can whip up a storm in the body, known as cytokine release syndrome (CRS). It’s like throwing a party and not knowing if the guests will have a good time or burn down the house. So, with the impending tsunami of BsAb use, the medical community is scrambling to figure out how to keep the party under control.

Enter the valiant clinicians, who’ve been trying to tame the beast using guidelines that were originally made for the CAR T-cell therapy crowd. But, plot twist—BsAbs and CAR T-cells are not exactly twinsies when it comes to side effects. So, what do we do? We call in the experts! A veritable Avengers team of physicians, nurses, and pharmacists from around the world, with their badges of experience from both clinical trials and real-world scenarios, have assembled to give us the playbook on how to handle the BsAb bash without any casualties. They’ve put their heads together to create a shiny set of consensus-based recommendations tailored to the unique drama that BsAbs bring to the table. Because, you know, personalized medicine is all the rage these days.